Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rosuvastatin: pharmacologic features].

Franco Bernini1, Alberico L Catapano

  • 1Dipartimento di Scienze Farmacologiche, Biologiche e Chimiche Applicate, Università degli Studi, Campus Universiario, 43100 Parma. fbernini@unipr.it

Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|February 27, 2004
PubMed
Summary

New statins, like rosuvastatin, offer enhanced safety and efficacy for treating atherosclerosis. Rosuvastatin demonstrates high potency and a favorable profile, aiding physicians in achieving patient lipid goals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.

BMJ open·2026
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine

Context:

  • Atherosclerosis poses a significant global health challenge, necessitating advanced therapeutic agents.
  • The development of novel HMG-CoA reductase inhibitors (statins) is crucial for expanding antiatherosclerotic treatment options.

Purpose:

  • To evaluate the pharmacological profile and clinical efficacy of rosuvastatin as a novel statin.
  • To assess rosuvastatin's potential in managing dyslipidemia and achieving therapeutic goals in patients.

Summary:

  • Rosuvastatin exhibits high enzyme affinity, hydrophilicity, selective hepatic action, and minimal CYP450 metabolism.
  • Clinically, it offers superior lipid-lowering efficacy compared to other statins, with a comparable safety profile.
  • It effectively reduces triglycerides and non-HDL cholesterol while increasing HDL cholesterol, with reduced drug interaction potential.

Related Experiment Videos

Impact:

  • Rosuvastatin expands the physician's toolkit for antiatherosclerotic therapy.
  • Its favorable profile supports improved patient outcomes and achievement of lipid management targets.
  • This contributes to the ongoing advancement of cardiovascular disease prevention and treatment strategies.